US market architecture for Geneva-headquartered family offices, biotech and medtech principals, engineering-commercial firms, and private-banking-adjacent operators. The Romandie commercial register reads as substance at home and as silence in Cambridge, Boston, and the American intermediary set.
The Geneva business is real. Standing on Quai du Mont-Blanc, in the Romandie biotech corridor, or inside the EPFL spinout cluster has been earned through decades of scientific rigour, regulatory cleanliness, and Swiss-French understatement. The pipeline asset works. The decision is made to put weight into the US market. A US subsidiary opens, a US licensing conversation begins, a US clinical site comes online, or a portfolio company starts its American commercialisation. The first ninety days do not match the model. US meetings happen. US follow-up goes cold.
The instinct is to stay precise, technically grounded, and let the data speak. The instinct is wrong for the American reader. Geneva commercial culture signals seriousness through specificity, restraint, and Romandie-tier credentials. US biotech and medtech buyers read the same restraint as missing category, missing US peer set, and missing outcome claim. The American evaluator does not interpret Swiss-French precision as authority. They interpret it as untranslated.
American buyers sort fast on three signals: category anchor, outcome claim, and US peer set. Geneva materials tend to omit the first two by design. The work is to translate the Swiss-French identity into US-legible visibility without hollowing out what carries at home.
The American buyer is not asking for louder. They are asking for the category, the outcome, and the peer set. Geneva firms omit those three by habit. House view on Geneva to US entry
The science is not the problem. The structure is not the problem. The American-facing architecture is.
Geneva family-office principals and portfolio holdings with US-facing positioning needs. Holding-brand versus operating-brand architecture, US intermediary-facing trust signals, and US co-investment materials.
Family offices in Geneva →Geneva private-client lawyers, tax advisors, and trust officers route through the wider Swiss fiduciary channel. Revenue-neutral, confidential, commission-free.
Swiss fiduciary channel →The specific shape of the Romandie biotech and medtech rebuild for Cambridge, Boston, and the wider US commercial set.
Geneva biotech, medtech, US →Six to ten weeks. Single US category, single corridor. The firm rebuilds positioning, pricing posture, messaging, and trust architecture for the American buyer, then launches it into market.
See the Sprint →Three to six months. Multi-channel US rebuild and run. Paid, owned, earned, conversion architecture, and sales enablement. The standard shape for Geneva principals committed to US scale.
See the Build →Monthly retainer, twelve-month minimum. Ongoing rebuild-and-run across multiple US surfaces. Typical for Geneva family offices and fiduciary-introduced portfolios with several US-facing brands or holdings.
See the Partnership →No legal services. No Swiss or Geneva-canton company formation, and no US entity formation. No FINMA licensing, L-1, E-2, EB-5, or O-1 visa work. No US tax structuring, FATCA analysis, or double-tax-treaty review. No US banking introductions. No fiduciary services. No regulatory licensing. No IP filing. No contract drafting.
These belong with Swiss counsel who specialise in US entry, and with US counsel on the American side. The firm works inside the parameters they set. When a marketing decision carries legal or tax implications, the firm flags it and defers before execution.
Geneva runs on Swiss-French understatement, private-banking heritage, and Romandie-tier credibility. American buyers filter on category anchor, outcome claim, and US peer set before anything else. The Geneva register that signals seriousness on Quai du Mont-Blanc reads as opaque or category-unmoored to a US biotech investor or Cambridge medtech evaluator. The firm does not change at the border. The reader does. The correction is register translation, not identity replacement.
Biotech, medtech, engineering-commercial firms, family-office-backed holdings, and private-banking-adjacent operators. The firm also works with Geneva-based fiduciaries introducing international principals to US operators. Fit is confirmed in discovery, not in published sector lists.
No. Swiss company formation, FINMA licensing, US LLC or C-corp formation, L-1, E-2, EB-5, and O-1 visa support, transfer pricing, US tax residency, and US banking introductions are handled by the principal's Swiss counsel and US counsel. The firm designs US marketing architecture inside the structure counsel has already put in place.
No. The firm does not pay referral commissions to Geneva lawyers, tax advisors, trust officers, or family offices who introduce principals. Introductions are revenue-neutral. The fiduciary retains the relationship with the principal. The firm delivers the US-facing work inside the structure the fiduciary already manages. Fiduciary introductions route through partnerships@globalmarketing.agency.
With an inquiry through the contact form and a short discovery conversation. The firm runs three engagements: Market Entry Sprint (6 to 10 weeks), Cross-Border Build (3 to 6 months), or Group Partnership (monthly retainer, 12-month minimum). Fit and pricing are confirmed in discovery, not published.
Playbook for Geneva and Romandie biotech and medtech principals carrying pipeline assets, IP, and licensing data into US commercialisation.
Read the piece →The Swiss-German pair to Geneva. Zurich family offices, fiduciaries, and medtech and biotech principals entering the US.
See Zurich corridor →The wider DACH gate for operators in Germany, Austria, Switzerland, and Liechtenstein.
See the DACH gate →